AI주식인사이트AI Stock Insight
D

에이프릴바이오

397030KOSDAQ

39.5 / 100

Reference Date: 2026-10-23

Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 26.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

April Bio is a research and development-focused company established in 2013, leveraging human antibody production and protein half-life extension technologies to develop antibody therapeutics and sustained recombinant protein drugs. Utilizing its core HuDVFab library and SAFA platform technologies, the company focuses on developing treatments for autoimmune and inflammatory diseases, generating revenue through global licensing agreements with pharmaceutical companies under its RIPCO business model.

Number of Employees

27people

Average Salary

201.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
3.70Industry Average 1.200.0Point

3.1x industry avg (risky)

ROE
-10.39Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
0.27Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼92.1% (1-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲41.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -1.9% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 12,930Won52-week high 73,30052-week low 11,870
1-month return0.0Point

1m -26.45% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral기업설명회(IR)개최2026-10-07
  • Neutral주식등의대량보유상황보고서(일반)2026-09-28